Therapy of Marfan Syndrome
- 1 February 2008
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 59 (1), 43-59
- https://doi.org/10.1146/annurev.med.59.103106.103801
Abstract
Marfan syndrome is a common inherited disorder of connective tissue caused by deficiency of the matrix protein fibrillin-1. Effective surgical therapy for the most life-threatening manifestation, aortic root aneurysm, has led to a nearly normal lifespan for affected individuals who are appropriately recognized and treated. Traditional medical therapies, such as beta-adrenergic receptor blockade, are used to slow pathologic aortic growth and decrease the risk of aortic dissection by decreasing hemodynamic stress. New insights regarding the pathogenesis of Marfan syndrome have developed from investigation of murine models of this disorder. Fibrillin-1 deficiency is associated with excess signaling by transforming growth factor beta (TGFβ). TGFβ antagonists have shown great success in improving or preventing several manifestations of Marfan syndrome in these mice, including aortic aneurysm. These results highlight the potential for development of targeted therapies based on discovery of disease genes and interrogation of pathogenesis in murine models.Keywords
This publication has 67 references indexed in Scilit:
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan SyndromeScience, 2006
- Usefulness of Enalapril Versus Propranolol or Atenolol for Prevention of Aortic Dilation in Patients With the Marfan SyndromeThe American Journal of Cardiology, 2005
- Replacement of the Aortic Root in Patients with Marfan's SyndromeNew England Journal of Medicine, 1999
- Cellular and extracellular biology of the latent transforming growth factor-β binding proteinsMatrix Biology, 1998
- Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndromeNature Genetics, 1996
- Life expectancy in the Marfan syndromeThe American Journal of Cardiology, 1995
- Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndromeThe American Journal of Cardiology, 1994
- Four Novel FBN1 Mutations: Significance for Mutant Transcript Level and EGF-like Domain Calcium Binding in the Pathogenesis of Marfan SyndromeGenomics, 1993
- The Cardiovascular Aspects of Marfan's Syndrome: A Heritable Disorder of Connective TissueCirculation, 1955